Remi A Nout

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1442501/publications.pdf

Version: 2024-02-01

105	8,167	76326	49909
papers	citations	40 h-index	87 g-index

105	105	105	6203
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancerâ€"Combined Analysis of the PORTEC Cohorts. Clinical Cancer Research, 2016, 22, 4215-4224.	7.0	535
2	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. International Journal of Gynecological Cancer, 2016, 26, 2-30.	2.5	515
3	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 295-309.	10.7	426
4	The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clinical and Translational Radiation Oncology, 2018, 9, 48-60.	1.7	415
5	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of Clinical Oncology, 2020, 38, 3388-3397.	1.6	398
6	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Modern Pathology, 2015, 28, 836-844.	5.5	343
7	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology, The, 2019, 20, 1273-1285.	10.7	305
8	Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer â€“ A pooled analysis of PORTEC 1 and 2 trials. European Journal of Cancer, 2015, 51, 1742-1750.	2.8	273
9	Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial. Journal of Clinical Oncology, 2009, 27, 3547-3556.	1.6	253
10	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clinical Cancer Research, 2015, 21, 3347-3355.	7.0	249
11	Bowel Function 14 Years After Preoperative Short-Course Radiotherapy and Total Mesorectal Excision for Rectal Cancer: Report of a Multicenter Randomized Trial. Clinical Colorectal Cancer, 2015, 14, 106-114.	2.3	231
12	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. Journal of the National Cancer Institute, 2015, 107, 402.	6.3	229
13	Long-Term Outcome and Quality of Life of Patients With Endometrial Carcinoma Treated With or Without Pelvic Radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) Trial. Journal of Clinical Oncology, 2011, 29, 1692-1700.	1.6	221
14	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. American Journal of Surgical Pathology, 2018, 42, 561-568.	3.7	214
15	Clinicopathological and molecular characterisation of â€˜multipleâ€classifierâ€™ endometrial carcinomas. Journal of Pathology, 2020, 250, 312-322.	4.5	205
16	Interpretation of somatic POLE mutations in endometrial carcinoma. Journal of Pathology, 2020, 250, 323-335.	4.5	203
17	ESMOâ€"ESGOâ€"ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Radiotherapy and Oncology, 2015, 117, 559-581.	0.6	167
18	Incorporation of molecular characteristics into endometrial cancer management. Histopathology, 2020, 76, 52-63.	2.9	163

#	Article	IF	Citations
19	Doseâ€“effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiotherapy and Oncology, 2016, 118, 160-166.	0.6	153
20	Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. European Journal of Cancer, 2012, 48, 1638-1648.	2.8	141
21	Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 1114-1126.	10.7	135
22	Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. Clinical Cancer Research, 2019, 25, 1087-1097.	7.0	113
23	Manifestation Pattern of Early-Late Vaginal Morbidity After Definitive Radiation (Chemo)Therapy and Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: An Analysis From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 88-95.	0.8	106
24	Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. International Journal of Radiation Oncology Biology Physics, 2015, 93, 797-809.	0.8	96
25	No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials. Journal of Clinical Oncology, 2015, 33, 1640-1646.	1.6	83
26	Health-related quality of life 14years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: Report of a multicenter randomised trial. European Journal of Cancer, 2014, 50, 2390-2398.	2.8	80
27	Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1088-1098.	0.8	77
28	High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecologic Oncology, 2014, 133, 197-204.	1.4	70
29	Posttraumatic Stress Disorder After High-Dose-Rate Brachytherapy for Cervical Cancer With 2 Fractions in 1 Application Under Spinal/Epidural Anesthesia: Incidence and Risk Factors. International Journal of Radiation Oncology Biology Physics, 2014, 89, 260-267.	0.8	68
30	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Modern Pathology, 2016, 29, 174-181.	5.5	68
31	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data metaâ€analysis. Cancer, 2021, 127, 2409-2422.	4.1	62
32	Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3Kâ€“AKT, Wnt/Î²-catenin and P53 pathway activation. Gynecologic Oncology, 2012, 126, 466-473.	1.4	60
33	Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials. International Journal of Radiation Oncology Biology Physics, 2015, 91, 530-539.	0.8	59
34	Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study. International Journal of Radiation Oncology Biology Physics, 2017, 98, 908-917.	0.8	59
35	Uterine serous carcinoma. Gynecologic Oncology, 2021, 162, 226-234.	1.4	58
36	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. Modern Pathology, 2017, 30, 459-468.	5.5	53

#	Article	IF	Citations
37	Adjuvant Treatment for POLE Proofreading Domainâ€“Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. Clinical Cancer Research, 2018, 24, 3197-3203.	7.0	50
38	Image-guided Adaptive Radiotherapy in Cervical Cancer. Seminars in Radiation Oncology, 2019, 29, 284-298.	2.2	47
39	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. Journal of the National Cancer Institute, 2021, 113, 1212-1220.	6.3	47
40	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nature Communications, 2022, 13, 1373.	12.8	47
41	Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery â€" A mono-institutional prospective study. Gynecologic Oncology, 2015, 136, 415-423.	1.4	46
42	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research, 2020, 8, 1508-1519.	3.4	45
43	A comprehensive longitudinal overview of health-related quality of life and symptoms after treatment for rectal cancer in the TME trial. Acta OncolÃ³gica, 2016, 55, 502-508.	1.8	44
44	The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends. Current Oncology Reports, 2011, 13, 472-478.	4.0	42
45	Ovarian function after ovarian transposition and additional pelvic radiotherapy: A systematic review. European Journal of Surgical Oncology, 2019, 45, 1328-1340.	1.0	40
46	Importance of Technique, Target Selection, Contouring, Dose Prescription, and Dose-Planning in External Beam Radiation Therapy for Cervical Cancer: Evolution of Practice From EMBRACE-I to II. International Journal of Radiation Oncology Biology Physics, 2019, 104, 885-894.	0.8	39
47	Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer. Lancet Oncology, The, 2020, 21, e157-e167.	10.7	39
48	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. Clinical Cancer Research, 2017, 23, 7232-7241.	7.0	37
49	Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 158, 312-320.	0.6	33
50	Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. Histopathology, 2019, 75, 128-136.	2.9	32
51	Recommendations from gynaecological (GYN) GEC-ESTRO working group â€" ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer. Radiotherapy and Oncology, 2020, 145, 36-44.	0.6	32
52	Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer. Seminars in Radiation Oncology, 2020, 30, 311-327.	2.2	32
53	Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 688-700.	0.8	31
54	Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. Oncotarget, 2016, 7, 39885-39893.	1.8	29

#	Article	IF	Citations
55	MRI-driven design of customised 3D printed gynaecological brachytherapy applicators with curved needle channels. 3D Printing in Medicine, 2019, 5, 8.	3.1	28
56	Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer. International Journal of Gynecological Pathology, 2022, 41, 220-226.	1.4	27
57	Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 158, 300-308.	0.6	23
58	Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.. Journal of Clinical Oncology, 2017, 35, 5502-5502.	1.6	23
59	Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors. Current Oncology Reports, 2019, 21, 83.	4.0	22
60	Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study. Radiotherapy and Oncology, 2019, 133, 176-182.	0.6	22
61	Late, Persistent, Substantial, Treatment-Related Symptoms After Radiation Therapy (LAPERS): A New Method for Longitudinal Analysis of Late Morbidityâ€"Applied in the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2020, 106, 300-309.	0.8	22
62	Education and training for image-guided adaptive brachytherapy for cervix cancerâ€"The (GEC)-ESTRO/EMBRACE perspective. Brachytherapy, 2020, 19, 827-836.	0.5	22
63	Clinical implementation of coverage probability planning for nodal boosting in locally advanced cervical cancer. Radiotherapy and Oncology, 2017, 123, 158-163.	0.6	21
64	Implementing an online radiotherapy quality assurance programme with supporting continuous medical education â€“ report from the EMBRACE-II evaluation of cervix cancer IMRT contouring. Radiotherapy and Oncology, 2020, 147, 22-29.	0.6	21
65	Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 975-986.	0.8	20
66	Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study. International Journal of Radiation Oncology Biology Physics, 2022, 112, 400-413.	0.8	20
67	Long-Term Health-Related Quality of Life in Patients With Rectal Cancer After Preoperative Short-Course and Long-Course (Chemo) Radiotherapy. Clinical Colorectal Cancer, 2016, 15, e93-e99.	2.3	19
68	Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer. International Journal of Gynecological Cancer, 2019, 29, 257-265.	2.5	18
69	Reporting of Late Morbidity After Radiation Therapy in Large Prospective Studies: A Descriptive Review of the Current Status. International Journal of Radiation Oncology Biology Physics, 2019, 105, 957-967.	0.8	17
70	Plan-library supported automated replanning for online-adaptive intensity-modulated proton therapy of cervical cancer. Acta OncolÃ³gica, 2019, 58, 1440-1445.	1.8	16
71	Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 161-173.	0.8	16
72	Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer. Radiotherapy and Oncology, 2020, 153, 114-121.	0.6	15

#	Article	IF	Citations
73	Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer. Oncotarget, 2017, 8, 25542-25551.	1.8	15
74	Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future. International Journal of Radiation Oncology Biology Physics, 2022, 112, 681-693.	0.8	14
75	Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network. Radiotherapy and Oncology, 2021, 155, 151-159.	0.6	13
76	Importance of training in external beam treatment planning for locally advanced cervix cancer: Report from the EMBRACE II dummy run. Radiotherapy and Oncology, 2019, 133, 149-155.	0.6	12
77	Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions. Expert Review of Anticancer Therapy, 2019, 19, 51-60.	2.4	12
78	Efficacy and toxicity of postoperative external beam radiotherapy or chemoradiation for early-stage cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 1878-1886.	2.5	12
79	Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1880.	3.7	12
80	Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 163, 150-158.	0.6	12
81	Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 112, 390-399.	0.8	12
82	Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. Gynecologic Oncology, 2021, 163, 117-124.	1.4	11
83	Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: An EMBRACE-I sub-study. Radiotherapy and Oncology, 2022, 168, 8-15.	0.6	11
84	A systematic review and meta-analysis of adjuvant chemotherapy after chemoradiation for locally advanced cervical cancer. Critical Reviews in Oncology/Hematology, 2022, 172, 103638.	4.4	8
85	Automated causal inference in application to randomized controlled clinical trials. Nature Machine Intelligence, 2022, 4, 436-444.	16.0	8
86	Rectal bleeding after radiation therapy for endometrial cancer. Radiotherapy and Oncology, 2015, 115, 240-245.	0.6	7
87	Single vocal cord irradiation for early-stage glottic cancer: Excellent local control and favorable toxicity profile. Oral Oncology, 2022, 127, 105782.	1.5	7
88	Initiatives for education, training, and dissemination of morbidity assessment and reporting in a multiinstitutional international context: Insights from the EMBRACE studies on cervical cancer. Brachytherapy, 2020, 19, 837-849.	0.5	6
89	Risk Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Analysis From the EMBRACE-I Study. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1177-1189.	0.8	6
90	Point: Vaginal brachytherapy should be a standard adjuvant treatment for intermediate-risk endometrial cancer. Brachytherapy, 2011, 10, 1-3.	0.5	5

#	Article	IF	Citations
91	Implementation of state-of-the-art (chemo)radiation for advanced cervix cancer in the Netherlands: A quality improvement program. Technical Innovations and Patient Support in Radiation Oncology, 2019, 9, 1-7.	1.9	4
92	Benefit of adaptive CT-based treatment planning in high-dose-rate endorectal brachytherapy for rectal cancer. Brachytherapy, 2018, 17, 78-85.	0.5	3
93	Primary Ewing sarcoma of the iris. Lancet, The, 2014, 383, 256.	13.7	2
94	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.. Journal of Clinical Oncology, 2015, 33, 5501-5501.	1.6	2
95	Rebuttal to Drs. Reed and Harrand. Brachytherapy, 2011, 10, 7.	0.5	1
96	Letter to the editor regarding â€œA systematic review comparing radiation toxicity after various endorectal techniquesâ€• Brachytherapy, 2019, 18, 564.	0.5	1
97	Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer. Indian Journal of Medical Research, 2021, 154, 303.	1.0	1
98	In Reply. Oncologist, 2014, 19, 1208-1208.	3.7	0
99	In Reply to Whitley etÂal. International Journal of Radiation Oncology Biology Physics, 2014, 90, 469-470.	0.8	0
100	Reply to M. Wissing et al. Journal of Clinical Oncology, 2017, 35, 1862-1862.	1.6	0
101	Investigators' response. Lancet Oncology, The, 2018, 19, 602.	10.7	0
102	Abstract IA004: Challenges for future adjuvant studies and the role of immunotherapy in endometrial cancer. , 2021, , .		0
103	Highlights from the recent 2020 Annual Global IGCS Meeting. Gynecologic Oncology, 2021, 161, 333-335.	1.4	0
104	Response to Yuce Sari et al.. Radiotherapy and Oncology, 2021, 158, 323-324.	0.6	0
105	An anthropomorphic deformable phantom of the vaginal wall and cavity. Biomedical Physics and Engineering Express, 2021, 7, 055019.	1.2	0